Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + gemcitabine + cisplatin
- Development stage
- Phase 3
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of cadonilimab, a novel tetravalent bispecific antibody targeting both PD-1 and CTLA-4 immune checkpoints, with gemcitabine and cisplatin, which are established chemotherapy agents. The combination leverages cadonilimab's dual immune checkpoint inhibition with the cytotoxic effects of gemcitabine and cisplatin. This regimen is being investigated for various advanced solid tumors, particularly in biliary tract cancers, gastric cancer, and potentially other indications where the individual components have shown efficacy.
- Brand names
- Kaitani
- Other names
- candonilimabAK104-201AK-104-201AK 104-201BicureX regimen
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cadonilimab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + gemcitabine + cisplatin.